CA2848403A1 - Hyr1-derived compositions and methods of treatment using same - Google Patents

Hyr1-derived compositions and methods of treatment using same Download PDF

Info

Publication number
CA2848403A1
CA2848403A1 CA2848403A CA2848403A CA2848403A1 CA 2848403 A1 CA2848403 A1 CA 2848403A1 CA 2848403 A CA2848403 A CA 2848403A CA 2848403 A CA2848403 A CA 2848403A CA 2848403 A1 CA2848403 A1 CA 2848403A1
Authority
CA
Canada
Prior art keywords
acinetobacter baumannii
protein
polypeptide
acinetobacter
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2848403A
Other languages
English (en)
French (fr)
Inventor
Ashraf S. Ibrahim
Michael R. Yeaman
John E. Edwards, Jr.
Guanpingsheng Luo
Yue Fu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center
Original Assignee
Los Angeles Biomedical Research Institute at Harbor-Ucla Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Los Angeles Biomedical Research Institute at Harbor-Ucla Medical Center filed Critical Los Angeles Biomedical Research Institute at Harbor-Ucla Medical Center
Publication of CA2848403A1 publication Critical patent/CA2848403A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/40—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2848403A 2011-09-14 2012-09-14 Hyr1-derived compositions and methods of treatment using same Abandoned CA2848403A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161534734P 2011-09-14 2011-09-14
US61/534,734 2011-09-14
US201161564201P 2011-11-28 2011-11-28
US61/564,201 2011-11-28
PCT/US2012/055604 WO2013040478A2 (en) 2011-09-14 2012-09-14 Hyr1-derived compositions and methods of treatment using same

Publications (1)

Publication Number Publication Date
CA2848403A1 true CA2848403A1 (en) 2013-03-21

Family

ID=47884005

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2848403A Abandoned CA2848403A1 (en) 2011-09-14 2012-09-14 Hyr1-derived compositions and methods of treatment using same

Country Status (11)

Country Link
US (1) US10160790B2 (https=)
EP (1) EP2755668A4 (https=)
JP (1) JP2014527084A (https=)
CN (1) CN103998049A (https=)
AU (1) AU2012308281A1 (https=)
BR (1) BR112014005773A2 (https=)
CA (1) CA2848403A1 (https=)
EA (1) EA025831B1 (https=)
GE (2) GEP20197052B (https=)
UA (1) UA115305C2 (https=)
WO (1) WO2013040478A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070077256A1 (en) 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
US10130691B2 (en) 2013-03-15 2018-11-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Compositions and methods for treating fungal and bacterial pathogens
EP2942389A1 (en) * 2014-05-05 2015-11-11 Servicio Andaluz De Salud Vaccine against Acinetobacter baumannii based on lipopolysaccharide-deficient cellular components
GB201503812D0 (en) * 2015-03-06 2015-04-22 Univ Aberdeen Antibody molecules and uses thereof
CN108472372B (zh) * 2015-07-13 2022-05-17 海港医学中心洛杉矶生物医学研究所 结合不动杆菌的抗体结合剂及其用途
EP3426287A4 (en) 2016-03-09 2020-03-11 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Methods and kits for use in preventing and treating vulvovaginal candidiasis
GB201902769D0 (en) * 2019-03-01 2019-04-17 Univ Court Of The Univ Of Aberdeen Antibody molcules and uses thereof
US20220354935A1 (en) * 2021-04-21 2022-11-10 Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center Vaccination against fungal epitopes to prevent inflammatory bowel diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100150942A1 (en) * 2008-12-03 2010-06-17 Cantor Thomas L Affinity purified human polyclonal antibodies and methods of making and using them
WO2011003085A1 (en) 2009-07-03 2011-01-06 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Hyr1 as a target for active and passive immunization against candida

Also Published As

Publication number Publication date
GEAP201913226A (en) 2019-07-10
UA115305C2 (uk) 2017-10-25
EP2755668A4 (en) 2015-07-01
CN103998049A (zh) 2014-08-20
BR112014005773A2 (pt) 2019-09-24
WO2013040478A2 (en) 2013-03-21
US20150191514A1 (en) 2015-07-09
WO2013040478A3 (en) 2013-06-27
AU2012308281A1 (en) 2014-04-24
EA201391199A1 (ru) 2014-04-30
US10160790B2 (en) 2018-12-25
JP2014527084A (ja) 2014-10-09
EA025831B1 (ru) 2017-02-28
EP2755668A2 (en) 2014-07-23
GEP20197052B (en) 2019-12-25

Similar Documents

Publication Publication Date Title
US10160790B2 (en) HYR1-derived compositions and methods of treatment using same
AU2014227748B2 (en) Compositions and methods for treating fungal and bacterial pathogens
JP5931724B2 (ja) ＳｔｒｅｐｔｏｃｏｃｃｕｓＰｎｅｕｍｏｎｉａｅに対するワクチンおよび組成物
JP5690822B2 (ja) カンジダに対する能動免疫及び受動免疫の標的としてのｈｙｒ１
US20140294930A1 (en) STREPTOCOCCAL GlcNAc-LACKING GLYCOPOLYPEPTIDES, CELL WALL CARBOHYDRATES, STREPTOCOCCUS VACCINES, AND METHODS FOR MAKING AND USING THEM
US9416173B2 (en) Peptide and conjugate vaccines for fungal infections
WO2014144024A1 (en) Hyr1 compositions and methods for treating fungal and bacterial pathogens
US20200222518A1 (en) Vaccine compositions and methods of using the same
US20160030533A1 (en) Compositions and methods of treating fungal and bacterial pathogens
US10590178B2 (en) Chimeric vaccine against fungal infections
WO2021151180A2 (pt) Anticorpo, seu uso, composição farmacêutica o compreendendo, método de diagnóstico de infecções fúngicas, kit de diagnóstico de infecções fúngicas e método para tratamento de infecções fúngicas
BR122023022739B1 (pt) Peptídeo mimético de leishmania spp. de seq id no: 3, método para o imunodiagnóstico de leishmanioses e composição imunogênica relacionada
BR122023022690B1 (pt) Peptídeo mimético de leishmania spp. de seq id no: 2, composição imunogênica e método para o imunodiagnóstico de leishmanioses relacionado
BR102015017724B1 (pt) Peptídeos miméticos de leishmania spp., processo para sua obtenção e aplicações

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20180914